CoChat

Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy

Open access
Sun, Jie, Bao, Siqi, Xu, Dandan, Zhang, Yan, Su, Jianzhong, Liu, Jiaqi, Hao, Dapeng, Zhou, Meng · 2019 · Cell Death & Disease

The DOI matches its Crossref record; 46 of the 46 references it cites were found in a registry or an index; 25 of the 46 sources its claims cite were checked for support.

Abstract

Heterogeneity in chemotherapeutic response is directly associated with prognosis and disease recurrence in patients with ovarian cancer (OvCa). Despite the significant clinical need, a credible gene signature for predicting response to platinum-based chemotherapy and for guiding the selection of personalized chemotherapy regimens has not yet been identified. The present study used an integrated approach involving both OvCa tumors and cell lines to identify an individualized gene expression signature, denoted as IndividCRS, consisting of 16 robust chemotherapy-responsive genes for predicting intrinsic or acquired chemotherapy response in the meta-discovery dataset. The robust performance of this signature was subsequently validated in 25 independent tumor datasets comprising 2215 patients and one independent cell line dataset, across different technical platforms. The IndividCRS was significantly correlated with the response to platinum therapy and predicted the improved outcome. Moreover, the IndividCRS correlated with homologous recombination deficiency (HRD) and was also capable of discriminating HR-deficient tumors with or without platinum-sensitivity for guiding HRD-targeted clinical trials. Our results reveal the universality and simplicity of the IndividCRS as a promising individualized genomic tool to rapidly monitor response to chemotherapy and predict the outcome of patients with OvCa.

Overview

CoChat Summary

## TL;DR

This study built a 16-gene individualized expression score, IndividCRS, from multiple ovarian cancer tumor and cell-line datasets to predict response to platinum-based chemotherapy. The score was validated across independent datasets and was associated with chemotherapy sensitivity, overall survival, homologous recombination deficiency, and epithelial-mesenchymal transition-related features.

## Key findings

  • The final signature contained 16 chemotherapy-responsive genes: 6 chemotherapy-sensitive genes (FZD4, MUTYH, PCK2, PEX10, SRPK1, UCP2) and 10 chemotherapy-resistant genes (EDIL3, GNG12, MBOAT2, MTMR6, NBR1, NEK7, NET1, PPP3CA, RAD17, WDR41).
  • In the meta-discovery datasets, patients with high IndividCRS scores (>0) had better outcomes and greater chemotherapy sensitivity; in Patch and TCGA, the score significantly stratified overall survival (Patch, P < 0.001; TCGA, P = 0.002), and the probability of complete response correlated with IndividCRS (r² = 0.88, P < 0.001).
  • Validation in independent datasets showed the same direction of effect: sensitive samples had higher IndividCRS than resistant samples in the GDSC cell line dataset (P = 0.041) and in three patient datasets (GSE3149, P = 0.001; GSE51373, P = 0.08; GSE23554, P = 0.011).
  • In the TCGA HR-defect analysis (n = 557), HR-defective tumors had significantly higher IndividCRS than HR-intact tumors, and the high-IndividCRS HR-defective group had better overall survival than the HR-intact group (P = 0.02). The overall prognostic meta-analysis across 21 datasets gave HR = 0.67 (95% CI 0.61–0.75, P < 0.001), and multivariable analysis gave HR = 1.54 (95% CI 1.35–1.76, P < 0.001).

## Methods

  • Retrospective integrated analysis of public gene-expression and clinical datasets from GEO, TCGA, and the literature: 29 ovarian cancer datasets total, including 3 cell-line datasets and 26 patient datasets, drawn from 12 microarray platforms and 2 RNA-seq platforms.
  • Four datasets with response information and larger sample sizes (Dressman, Patch, TCGA, and GSE47856) were used as the meta-discovery set; the remaining 25 datasets were used for independent validation.
  • Differential expression was assessed with limma for microarray data and edgeR for RNA-seq data; genes present in at least 3 of the 4 discovery datasets were used to build the 16-gene IndividCRS, and survival/association analyses used Kaplan–Meier, log-rank tests, Wilcoxon tests, t-tests, and meta-analysis.

## Limitations

  • The paper states that the signature is “merely a reflective signature of the underlying mechanisms of chemo-response,” and that functional studies are still required.
  • The paper also notes that the relationship between IndividCRS and HR deficiency “need be further investigated using functional experiments.”
  • Evident from the text: the study is retrospective and based on public datasets, so its findings depend on existing cohort annotation and platform-specific data quality rather than prospective clinical testing.

Model-written summary. Check it against the paper before relying on it.

Integrity signals

Registry

Crossref · 10.1038/s41419-019-1874-9

Cites

46 of 46 references verified0 citation errors · 0 not checkable

Statistics

Nothing to recompute.

Figures

Fig. 1 Development of a 16-gene signature. a Forest plot illustrating the Hazard ratios (HRs) of fixed-effect meta-analysis summary result for each of the 16 chemotherapy-responsive genes. The HR shown for each gene is leveraged from univariate and multivariate Cox-PH analysis across 21 ovarian cancer cohorts. Colored rectangles on the left indicate the logFC of gene expression comparing chemo-sensitive to chemo-resistant tumors. b Kaplan–Meier curves of OS for patients divided by the IndividCRS in the Patch and TCGA datasets. Significance was determined using the log-rank test. c Distribution of the IndividCRS and expression heatmap of 16 chemotherapy-responsive genes in the Patch and TCGA datasets. HR, hazard ratio; OS, overall survival; IndividCRS, individual chemotherapeutic response scores; TCGA, The Cancer Genome Atlas Network; CR: Complete response; PR: partial response; PD: progression disease; SD: stable disease
Fig. 1 Development of a 16-gene signature. a Forest plot illustrating the Hazard ratios (HRs) of fixed-effect meta-analysis summary result for each of the 16 chemotherapy-responsive genes. The HR shown for each gene is leveraged from univariate and multivariate Cox-PH analysis across 21 ovarian cancer cohorts. Colored rectangles on the left indicate the logFC of gene expression comparing chemo-sensitive to chemo-resistant tumors. b Kaplan–Meier curves of OS for patients divided by the IndividCRS in the Patch and TCGA datasets. Significance was determined using the log-rank test. c Distribution of the IndividCRS and expression heatmap of 16 chemotherapy-responsive genes in the Patch and TCGA datasets. HR, hazard ratio; OS, overall survival; IndividCRS, individual chemotherapeutic response scores; TCGA, The Cancer Genome Atlas Network; CR: Complete response; PR: partial response; PD: progression disease; SD: stable diseaseCC BY · PubMed Central
Fig. 2 Association between the IndividCRS and chemotherapy response in four independent datasets. Violin Plot illustrating the distribution and probability density of the IndividCRS, and the distribution of the IndividCRS and expression heatmap of 16 chemotherapy-responsive genes in the a GDSC dataset, b GSE3149 dataset, c GSE51373 dataset, and d GSE23554 dataset. Patients with chemotherapy sensitivity exhibited higher IndividCRS than those with chemotherapy resistance. Significance was determined using an unpaired t-test. IndividCRS, individual chemotherapeutic response scores
Fig. 2 Association between the IndividCRS and chemotherapy response in four independent datasets. Violin Plot illustrating the distribution and probability density of the IndividCRS, and the distribution of the IndividCRS and expression heatmap of 16 chemotherapy-responsive genes in the a GDSC dataset, b GSE3149 dataset, c GSE51373 dataset, and d GSE23554 dataset. Patients with chemotherapy sensitivity exhibited higher IndividCRS than those with chemotherapy resistance. Significance was determined using an unpaired t-test. IndividCRS, individual chemotherapeutic response scoresCC BY · PubMed Central
Fig. 3 Association between the IndividCRS and HRD. a Pairwise comparison of the IndividCRS between HR-intact tumors and HR-defective tumors including those with a BRCA mutation, BRCA methylation, EMSY amplification, and defects in PTEN and FA genes. Significance was determined using the Wilcoxon rank-sum test. b Kaplan–Meier curves of OS for high IndividCRS HR-defective tumors and low IndividCRS HR-defective tumors versus HR-intact tumors. The high IndividCRS group of HR-defective tumors showed significantly improved OS, whereas low IndividCRS group of HR-defective tumors showed no significant difference in OS compared with HR-intact tumors. Significance was determined using the log-rank test. c Kaplan–Meier curves of OS for high IndividCRS BRCA-deficient tumors and low IndividCRS BRCA-deficient tumors versus BRCA1/2-intact tumors. The high IndividCRS group of BRCA-deficient tumors showed significantly improved OS, whereas low IndividCRS group of BRCA-deficient tumors showed no significant difference in OS compared with BRCA1/2-intact tumors. Significance was determined using the log-rank test. IndividCRS, individual chemotherapeutic response scores; HRD, homologous recombination deficiency; PTEN, phosphatase and tensin homolog; FA, Fanconi anemia; OS, overall survival
Fig. 3 Association between the IndividCRS and HRD. a Pairwise comparison of the IndividCRS between HR-intact tumors and HR-defective tumors including those with a BRCA mutation, BRCA methylation, EMSY amplification, and defects in PTEN and FA genes. Significance was determined using the Wilcoxon rank-sum test. b Kaplan–Meier curves of OS for high IndividCRS HR-defective tumors and low IndividCRS HR-defective tumors versus HR-intact tumors. The high IndividCRS group of HR-defective tumors showed significantly improved OS, whereas low IndividCRS group of HR-defective tumors showed no significant difference in OS compared with HR-intact tumors. Significance was determined using the log-rank test. c Kaplan–Meier curves of OS for high IndividCRS BRCA-deficient tumors and low IndividCRS BRCA-deficient tumors versus BRCA1/2-intact tumors. The high IndividCRS group of BRCA-deficient tumors showed significantly improved OS, whereas low IndividCRS group of BRCA-deficient tumors showed no significant difference in OS compared with BRCA1/2-intact tumors. Significance was determined using the log-rank test. IndividCRS, individual chemotherapeutic response scores; HRD, homologous recombination deficiency; PTEN, phosphatase and tensin homolog; FA, Fanconi anemia; OS, overall survivalCC BY · PubMed Central
Fig. 4 Association between the IndividCRS and enhanced resistance in samples treated with multiple cycles of chemotherapy. a Pairwise comparison of the IndividCRS in 46 cell lines before and after 48 h treatment with cisplatin. Significance was determined using a paired t-test. b Violin Plot illustrating the distribution and probability density of the IndividCRS in samples before and after five rounds of cisplatin treatment. Significance was determined using a paired t-test. c Pairwise comparison of the IndividCRS in patients before and after three cycles of carboplatin treatment. Significance was determined using a paired t-test. d Pairwise comparison of the IndividCRS in samples before and after three cycles of paclitaxel treatment. Significance was determined using paired t-test. e Pairwise comparison of the IndividCRS in samples post- and pre-chemotherapy. Significance was determined using an unpaired t-test. IndividCRS, individual chemotherapeutic response scores
Fig. 4 Association between the IndividCRS and enhanced resistance in samples treated with multiple cycles of chemotherapy. a Pairwise comparison of the IndividCRS in 46 cell lines before and after 48 h treatment with cisplatin. Significance was determined using a paired t-test. b Violin Plot illustrating the distribution and probability density of the IndividCRS in samples before and after five rounds of cisplatin treatment. Significance was determined using a paired t-test. c Pairwise comparison of the IndividCRS in patients before and after three cycles of carboplatin treatment. Significance was determined using a paired t-test. d Pairwise comparison of the IndividCRS in samples before and after three cycles of paclitaxel treatment. Significance was determined using paired t-test. e Pairwise comparison of the IndividCRS in samples post- and pre-chemotherapy. Significance was determined using an unpaired t-test. IndividCRS, individual chemotherapeutic response scoresCC BY · PubMed Central
Fig. 5 Association between platinum resistance and EMT. a Pairwise comparison of the IndividCRS in four OvCa subtypes, including immunoreactive, differentiated, proliferative and mesenchymal. Significance was determined using the Wilcoxon rank-sum test. b Bubble plot showing the correlation between the IndividCRS and EMT score, ZEB1 and Ki67 across 19 patient datasets. The size of the circles proportional to the significance of the correlation and the color of the border indicates Pearson correlation coefficients. Correlation of the IndividCRS with EMT score in the c TCGA dataset and d Patch dataset, and e ZEB1 in the Patch dataset. The orange line represents the line of linear regression through the data points. EMT, epithelial-mesenchymal transition; IndividCRS, individual chemotherapeutic response scores; OvCa, ovarian cancer; ZEB1, zinc finger E-box binding homeobox 1
Fig. 5 Association between platinum resistance and EMT. a Pairwise comparison of the IndividCRS in four OvCa subtypes, including immunoreactive, differentiated, proliferative and mesenchymal. Significance was determined using the Wilcoxon rank-sum test. b Bubble plot showing the correlation between the IndividCRS and EMT score, ZEB1 and Ki67 across 19 patient datasets. The size of the circles proportional to the significance of the correlation and the color of the border indicates Pearson correlation coefficients. Correlation of the IndividCRS with EMT score in the c TCGA dataset and d Patch dataset, and e ZEB1 in the Patch dataset. The orange line represents the line of linear regression through the data points. EMT, epithelial-mesenchymal transition; IndividCRS, individual chemotherapeutic response scores; OvCa, ovarian cancer; ZEB1, zinc finger E-box binding homeobox 1CC BY · PubMed Central
Fig. 6 Prognostic value of the IndividCRS in predicting clinical outcome. a, b Kaplan–Meier curves of OS for patients in low IndividCRS and high IndividCRS subgroups. Significance was determined using the log-rank test. b Forest plot illustrating the HRs of survival analyses of low-IndividCRS group versus high-IndividCRS in 21 patient datasets. Significance was determined using the Cox proportional hazards model. The red diamond indicates the fixed-effects meta-analysis summary of HRs over 21 datasets. c Multivariable analyses using Cox proportional hazards models were performed for all patients in 21 datasets. IndividCRS, individual chemotherapeutic response scores; OS, overall survival; HR, hazard ratio, CI, confidence interval
Fig. 6 Prognostic value of the IndividCRS in predicting clinical outcome. a, b Kaplan–Meier curves of OS for patients in low IndividCRS and high IndividCRS subgroups. Significance was determined using the log-rank test. b Forest plot illustrating the HRs of survival analyses of low-IndividCRS group versus high-IndividCRS in 21 patient datasets. Significance was determined using the Cox proportional hazards model. The red diamond indicates the fixed-effects meta-analysis summary of HRs over 21 datasets. c Multivariable analyses using Cox proportional hazards models were performed for all patients in 21 datasets. IndividCRS, individual chemotherapeutic response scores; OS, overall survival; HR, hazard ratio, CI, confidence intervalCC BY · PubMed Central

Verification

Claims the paper makes

19 Valid · 0 Not valid · 6 Not checked · 48 Own results and interpretations

38 more claims

Create a free account to see all 73 claims and to verify the 7 references still open.

See all claims — free account
  • It may state two separate claims as one. 17
  • Probably not a substantial claim. 19

Create a free account to see these claims.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 46 references

Cited by

See all 23

Metadata

Authors
Sun, J., Bao, S., Xu, D., Zhang, Y., Su, J., Liu, J., Hao, D., & Zhou, M.
Affiliations
  • Wenzhou Medical University (CN)
  • Harbin University (CN)
  • Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
  • University of Macau (MO)
Corresponding author
  • Hao, Dapeng
  • Zhou, Meng
Venue
Cell Death & Disease
Published
2019-09-10
Volume
10
Issue
9
Pages
661-661
ISSN
2041-4889 (ISSN-L)
OpenAlex
W2972563948
Cited by
23
References
46
Citations by year
2026: 3 · 2025: 1 · 2024: 1 · 2023: 3 · 2022: 2 · 2021: 5 · 2020: 8
FWCI
3.59
Type
journal article
Language
en
Open access
Licence
Locations
  • Cell Death and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
Funders
  • Wenzhou Medical University (QTJ18023, QTJ18029, QTJ18024)
  • National Natural Science Foundation of China (31701153)
  • Wenzhou Institute of Biomaterials and Engineering
Topics
  • Health Sciences › Medicine › Oncology › Ovarian cancer diagnosis and treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gene expression and cancer classification
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
Keywords
ovarian cancer, platinum-based chemotherapy, chemotherapy response prediction, gene expression signatures, tumor heterogeneity, homologous recombination deficiency, personalized chemotherapy, acquired drug resistance, prognostic factors
MeSH terms
Female, Humans, Ovarian Neoplasms, Platinum, Biomarkers, Tumor, Gene Expression Regulation, Neoplastic, Databases, Nucleic Acid, Cell Line, Tumor

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

The claim verdicts this report counts are experimental: their accuracy is not yet measured.

A language model drew the claims from the paper on 2026-10-10, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).

A second model labelled each claim on 2026-10-10 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).

Cited sources are checked with a language model’s help (gpt-6-sol).

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy. https://app.cochat.ai/papers/10.1038/s41419-019-1874-9
The paper
Sun, J., Bao, S., Xu, D., Zhang, Y., Su, J., Liu, J., Hao, D., & Zhou, M. (2019). Large-scale integrated analysis of ovarian cancer tumors and cell lines identifies an individualized gene expression signature for predicting response to platinum-based chemotherapy. Cell Death & Disease. https://doi.org/10.1038/s41419-019-1874-9

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.